DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on November 15, 2006; DOI: 10.1124/dmd.106.012369

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.012369v1
35/2/201    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, Q.
Right arrow Articles by Morris, M. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, Q.
Right arrow Articles by Morris, M. E


Received for publication August 4, 2006.
Revised November 6, 2006.
Accepted for publication November 8, 2006.

Flavonoids modulate Monocarboxylate transporter-1 mediated transport of {gamma}-hydroxybutyrate in vitro and in vivo

Qi Wang 1 Marilyn E Morris 1*

1 University at Buffalo

* Address correspondence to: E-mail: memorris{at}buffalo.edu

Abstract

The objective of this study was to determine the effects of flavonoids on the in vitro Monocarboxylate Transporter 1 (MCT1)-mediated transport and in vivo disposition of the drug of abuse, {gamma}-hydroxybutyrate (GHB). The uptake of GHB in rat MCT1 gene-transfected MDA-MB231 cells was significantly decreased in the presence of the flavonoids apigenin, biochanin A, chrysin, diosmetin, fisetin, genistein, hesperitin, kaempferol, luteolin, morin, narigenin, phloretin and quercetin, but was not affected by the flavonoid glycosides phloridzin and rutin. The IC50 values for luteolin, morin and phloretin were 0.41 ± 0.14, 6.41 ± 2.01 and 2.57 ± 0.48 µM, with the inhibition mechanism for luteolin being competitive. 3H-kaempferol and 3H-biochanin A did not exhibit MCT1-mediated uptake, suggesting that these flavonoids are not substrates for MCT1. The combination of luteolin and phloretin inhibited the uptake of GHB in a synergistic manner; however, the combination of luteolin and morin was antagonistic. GHB 1000 mg/kg was administered to rats by iv bolus, with or without the concomitant administration of luteolin 10 mg/kg iv. Following luteolin treatment, the renal and total clearances of GHB were significantly increased, likely due to inhibition of the MCT1-mediated renal reabsorption of GHB, and the sleep time significantly decreased (121 ± 5 min versus 165 ± 10 min) compared with control rats. Overall the results of this study indicate that flavonoids from food or herbal products may significantly alter the pharmacokinetics and pharmacodynamics of MCT substrates.


Key words: membrane transport, organic anion transport, pharmacokinetics, renal transport, toxicokinetics, transporters


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Harris, G. Eliyahu, L. Frydman, and H. Degani
Kinetics of hyperpolarized 13C1-pyruvate transport and metabolism in living human breast cancer cells
PNAS, October 27, 2009; 106(43): 18131 - 18136.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Cui and M. E. Morris
The Drug of Abuse {gamma}-Hydroxybutyrate Is a Substrate for Sodium-Coupled Monocarboxylate Transporter (SMCT) 1 (SLC5A8): Characterization of SMCT-Mediated Uptake and Inhibition
Drug Metab. Dispos., July 1, 2009; 37(7): 1404 - 1410.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.